Genomic Vision: High Attendance at the 1st US Satellite Symposium on Molecular Combing
11 Septembre 2017 - 8:00AM
Business Wire
- Genomic Vision organized its first
workshop in the US during the renowned Eukaryotic DNA Replication
& Genome Maintenance Meeting in Cold Spring Harbor (NYC,
USA)
- The KOL’s confirmed Molecular Combing
as an increasingly recognized technology for studying DNA
replication dynamics
- Genomic Vision presented a set of
proprietary tools including a new version of FiberStudio®, its
software dedicated to multiple applications for DNA analysis
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics and technology company specialized in the
development of single DNA detection tools for research and in vitro
diagnostic, announced today that it was invited to hold a special
symposium dedicated to the robustness of single-molecule techniques
for DNA replication analysis. The presentation took place on
September 6, 2017, during the broad-based DNA replication and
Genome Maintenance meeting, hosted for over 10 years in Cold Spring
Harbor (NYC, USA). Over 300 participants attended the event.
The workshop was introduced by Prof. Susan Gerbi (Brown
University), the recipient of many awards for her research and a
long-time collaborator of Genomic Vision. This introduction on
fiber assays’ history and their evolution through time was followed
by two short talks.
First, Erin Sybouts presented her PhD work conducted at the
University of Texas Health Science Center at San Antonio in Dr Alex
Bishop’s laboratory, and focused on the whole-genome analysis of
replication fork defects by molecular combing in various genetic
conditions. Then, Dr. Yannick Delpu presented his post-doctoral
work conducted at the New York University in Dr Mamta
Tahiliani’s laboratory about the benefits of Molecular Combing
technology to address various critical issues, notably while
studying replication at a specific locus.
“I am very encouraged to see the user-friendly tools being
developed for combing. It is going to make the technology available
to a lot more people and greatly expand the adoption of single
molecule DNA replication technique,” declared Prof.
Nicholas Rhind, University of Massachusetts Medical School.
Genomic Vision, represented by Dr Julien Cottineau, also
presented a new version of its FiberStudio® software that meets the
needs of its clients across various sectors such as academic
research, drug discovery and gene editing industry and clinical
diagnostics. Based on advanced image and data processing algorithms
as well as recent Machine Learning approaches, FiberStudio®
automatically detects, measures and classifies linear objects of
stretched DNA molecules in order to provide users and clinicians
with comprehensive reports showing complex structural variations,
spatiotemporal analysis of DNA replication and a number of other
applications.
“This first satellite symposium rewards our marketing efforts in
the U.S. Our successful exposure to major KOL’s in the field of DNA
replication demonstrates the potential of molecular combing
technology to identify and counter damages in DNA replication that
causes critical genetic alterations,” concluded Stephane
Altaba, ýExecutive Vice-President Corporate Development at
Genomic Vision.
ABOUT GENOMIC VISION GENOMIC VISION is a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research. Through the DNA Molecular Combing, a
strong proprietary technology allowing to identify genetic
abnormalities, GENOMIC VISION stimulates the R&D productivity
of the pharmaceutical companies, the leaders of the diagnostic
industry and the research labs. The Company develops a robust
portfolio of diagnostic tests (breast, ovarian and colorectal
cancers, myopathies) and analysis tools (DNA replication,
biomarkers discovery, gene editing quality control). Based near
Paris, in Bagneux, the Company has approximately 60 employees.
GENOMIC VISION is a public listed company listed in compartment C
of Euronext’s regulated market in Paris (Euronext: GV - ISIN:
FR0011799907). For further information, please visit
www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170910005096/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorPress RelationsBruno
Arabian, +33 1 81 70 96
30barabian@ulysse-communication.comorNewCapInvestor
RelationsDušan Orešanský / Emmanuel Huynh, +33 1 44 71 94
92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024